iShares Global Clean Energy ETF vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? iShares Global Clean Energy ETF trades at $17.28 (market cap $2.30B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.34 (market cap $2.28B). The key difference: iShares Global Clean Energy ETF and SELLAS Life Sciences Group Inc. Common Stock are close in size by market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals.
| ICLN | SLS | |
|---|---|---|
Market Cap | $2.30B | $2.28B |
Volume | 3,661,617 | 3,128,960 |
52-Week High | $23.75 | $15.46 |
52-Week Low | $15.78 | $1.39 |
Typical Hold Time | 87 Days | — |
Sector | — | Health |
Enterprise Value | — | $2.15B |
Signals from Pluang's Aura AI — not financial advice
ICLN trades at $17.31, down 1.31% with a bearish technical signal from moving averages. The ETF faces volatility with clean energy exposure showing deeper drawdowns compared to traditional energy peers. Recent news highlights competitive pressure from fossil fuel ETFs delivering stronger returns and lower fees, though geopolitical tensions are accelerating global renewable energy adoption.
The outlook remains challenged by high expense ratios and sector volatility, but long-term growth potential exists from global energy transition trends. Key risks include competitive pressure from traditional energy and execution challenges in renewable adoption timelines.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →